-
公开(公告)号：US08178093B2
公开(公告)日：2012-05-15
申请号：US12502920
申请日：2009-07-14
申请人： Roland Beliard , Dominique Bourel , Amaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Amaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcγ受体并具有特定的聚糖结构。 本发明的抗D抗体可用于预防Rh阴性人中的恒河猴异免疫，特别是新生婴儿中的溶血性疾病或特发性血小板减少性紫癜（ITP）等用途。
-
公开(公告)号：US08153124B2
公开(公告)日：2012-04-10
申请号：US12502915
申请日：2009-07-14
申请人： Roland Beliard , Dominique Bourel , Amaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Amaud Glacet , Christophe de Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcγ受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人体中的恒河猴同种免疫，特别是新生婴儿中的溶血性疾病或特发性血小板减少性紫癜（ITP）等用途。
-
23.发明申请Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity 审中-公开抗恒河猴和抗hla-dr抗体的岩藻糖含量/半乳糖含量比与adcc活性的相关性公开(公告)号：US20070015239A1
公开(公告)日：2007-01-18
申请号：US10575333
申请日：2004-10-20
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/2833 , C07K16/34 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： The present invention relates to monoclonal antibodies with high ADCC activity, characterised in having glycannic structures with a ratio (fucose content/galactose content) of 0.6 or less on the glycosylation site thereof in the Fc region. The invention also relates to pharmaceutical compositions, containing said monoclonal antibodies with high effector activity.
摘要翻译： 本发明涉及具有高ADCC活性的单克隆抗体，其特征在于具有在Fc区的糖基化位点上具有0.6或更小比例（岩藻糖含量/半乳糖含量）的甘氨酸结构。 本发明还涉及含有具有高效应物活性的所述单克隆抗体的药物组合物。
-
公开(公告)号：US20070009522A1
公开(公告)日：2007-01-11
申请号：US11517525
申请日：2006-09-08
申请人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe Romeuf , Nicolas Bihoreau , Emmanuel Nony
发明人： Roland Beliard , Dominique Bourel , Arnaud Glacet , Christophe Romeuf , Nicolas Bihoreau , Emmanuel Nony
IPC分类号： A61K39/395 , C07K16/40 , C07K16/28
CPC分类号： C07K16/34 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/41 , C07K2317/52 , C07K2317/732
摘要： The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP)
摘要翻译： 本发明涉及通过ADDC型测试获得和选择单克隆抗体的方法，所述抗体能够激活III型Fcy受体并具有特定的聚糖结构。 本发明的抗-D抗体可用于预防Rh阴性人中的恒河猴同种免疫，特别是用于新生婴儿如特发性血小板减少性小蛹9ITP的溶血性疾病）
-
25.发明申请MODIFIED HUMAN FACTOR VII/VIIA AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME 审中-公开改良人因子VII / VIIA及含有其的药物组合物公开(公告)号：US20110162094A1
公开(公告)日：2011-06-30
申请号：US12664733
申请日：2008-06-12
申请人： Emmanuel Nony , Sami Chtourou , Nicolas Bihoreau
发明人： Emmanuel Nony , Sami Chtourou , Nicolas Bihoreau
IPC分类号： A01K67/027 , C12N9/64 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/00 , A01K67/00 , A01H5/00 , A01K67/033 , A61K38/48 , A61P7/04
CPC分类号： A61K38/4846 , C12N9/6437 , C12Y304/21021
摘要： Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same.
摘要翻译： 具有高稳定性的修饰因子VII / VIIa，编码这种修饰因子VII / VIIa的核酸及其制备方法。
-
26.发明申请RECOMBINANT OR TRANSGENIC FACTOR VII COMPOUND HAVING A MAJORITY OF GLYCAN, BIANTENNARY, BISIALYLATED AND NON-FUCOSYLATED FORMS 审中-公开重组或转基因VII化合物，主要含有甘氨酸，二元醇，双联异构体和非结构化形式公开(公告)号：US20090239788A1
公开(公告)日：2009-09-24
申请号：US12374269
申请日：2007-07-31
CPC分类号： C12N9/50 , A01K2217/05 , A01K2227/107 , A01K2267/01 , A61K38/00 , C07K14/745 , C12N9/6437 , C12N9/647 , C12Y304/21021
摘要： The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such a compound for use as a medication, and a method for preparing said compound, among others.
摘要翻译： 本发明涉及重组或转基因因子VII化合物，具有与N-糖基化位点连接的聚糖形式的化合物的每个因子VII分子，其中在所述化合物中的所有因子VII分子中，聚糖，双天冬氨酸，双重化和非岩藻糖基化形式 是大多数。 本发明还涉及这种用作药物的化合物，以及制备所述化合物的方法等。
-
27.发明申请RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, EACH FACTOR VII MOLECULE HAVING TWO N-GLYCOSYLATION SITES WITH DEFINED GLYCAN UNITS 审中-公开重组或转基因因子VII组成，每个因子VII分子具有两个定义的糖原单位的N-糖苷化位点公开(公告)号：US20090311239A1
公开(公告)日：2009-12-17
申请号：US12300486
申请日：2007-05-31
CPC分类号： C12N9/6437 , A01K67/0275 , A01K2217/05 , A01K2227/107 , A01K2267/01 , A61K38/00 , C12N15/8509 , C12Y304/21021
摘要： The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII
摘要翻译： 本发明涉及重组或转基因因子VII的组合物，组合物的每个因子VII的分子表现出两个N-糖基化位点，其中，在组合物的FVII的所有分子中，Galalpha1,3Gal聚糖部分的比例为 在0％到4％之间。 本发明还涉及制备这种FVII组合物的方法
-
公开(公告)号：US10344272B2
公开(公告)日：2019-07-09
申请号：US12300486
申请日：2007-05-31
IPC分类号： C12N9/64 , A61K38/36 , C12N15/85 , A01K67/027 , A61K38/00
摘要： The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the proportion of Galα1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.
-
29.发明申请METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY 审中-公开用于鉴定感染细胞宿主的方法，用于确定患者是如何开发监管或免疫反应，并确定对免疫应答的反应公开(公告)号：US20140377761A1
公开(公告)日：2014-12-25
申请号：US14343480
申请日：2012-09-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6881 , C12Q2600/136 , C12Q2600/158
摘要： The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
摘要翻译： 本发明涉及用于确定树突状细胞是否属于耐受性树突状细胞亚群或效应性树突状细胞亚群的方法，以及用于确定进行免疫治疗的患者和/或已经用疫苗给药的方法正在开发一种 针对调节性T细胞应答或效应T细胞应答的免疫应答以及确定免疫治疗反应的方法。
-
公开(公告)号：US09868770B2
公开(公告)日：2018-01-16
申请号：US13109491
申请日：2011-05-17
申请人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
发明人： Véronique Bordas , Laetitia Bussieres , Sabi Airouche , Sophie Tourdot , Emmanuel Nony , Philippe Moingeon , Julien Bouley
IPC分类号： C07H21/02 , C07H21/04 , C12N1/00 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/04 , C12P21/06 , C07K14/435 , C12N1/16 , C12P21/00
CPC分类号： C07K14/43531 , C07H21/02 , C07H21/04 , C12N1/00 , C12N1/16 , C12N1/20 , C12N15/00 , C12N15/09 , C12P21/00
摘要： The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.031 秒)
